Comparative Pharmacology
Head-to-head clinical analysis: MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIVACURIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIVACURIUM CHLORIDE.
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER vs MIVACURIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarization and muscle contraction.
Mivacurium chloride is a non-depolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor end-plate, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission. It is a mixture of stereoisomers and is rapidly hydrolyzed by plasma cholinesterase.
Initial IV bolus of 0.15-0.2 mg/kg (following succinylcholine) or 0.25 mg/kg (without succinylcholine) over 30-60 seconds. Maintenance infusion: 8-10 mcg/kg/min for continuous neuromuscular blockade during anesthesia.
0.15-0.25 mg/kg IV bolus for endotracheal intubation; maintenance infusion: 0.5-1.5 mcg/kg/min IV
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 minutes (0.03-0.05 h) due to rapid hydrolysis by plasma esterases; clinical duration is short, with recovery of neuromuscular function beginning within 5-10 minutes after bolus dose.
Terminal elimination half-life is approximately 2 minutes (range 1-3 minutes) for the initial rapid distribution phase, and the elimination half-life is about 17-20 minutes in patients with normal renal function. Clinically, this short half-life allows for rapid recovery of neuromuscular function.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of the dose; biliary/fecal elimination accounts for the remainder, primarily as metabolites via the liver.
Primarily renal excretion of unchanged drug and metabolites; approximately 90-95% eliminated via urine, with less than 5% in feces. Minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker